Recent/Relevant Papers:
(* signifies Goldkorn Lab trainees):
Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N. External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer. Mol Cancer Ther. 2022 Dec 2;21(12):1857-1861. PMID: 36198026.
Agarwal N, et al, Goldkorn A, et al, and Quinn DI. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin. Onc., In Press. PMID: 35446628.
*Xu T, Jung JA, Delfarah A, *Lu Y-T, Arenasano C, *Iqbal M, *Delijani K, *Hsieh T-C, *Hodara E, Mehta HH, Cohen P, Graham NA, Fraser SE, and Goldkorn A. Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time. Sci Rep 2022, 12:5518. PMID: 35365706.
*Lu Y-T, *Xu T, *Iqbal M, *Hsieh T-C, Juo Z, Liang G, Farnham JP, Rhie SK and Goldkorn A. FOXC1 binds enhancers and promotes cisplatin resistance in bladder cancer. Cancers 2022, 14, 1717. PMID: 35406487.
*Morrison G, Buckley J, Ostrow D, Varghese B, Cen SY, Werbin J, Ericson N, *Cunha A, *Lu Y-T, George T, Smith J, Quinn D, Duddalwar V, Triche T, and Goldkorn A. Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. Int J. Mol. Sci, 2022, 23, 2571. PMID: 35269713.
Flaig T, Tangen C, Daneshmand S, Alva A, Lerner S, Lucia M, McConkey D, Theodorescu D, Goldkorn A, et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin Cancer Res, 2021. PMID: 33568346.
Goldkorn A, Tangen C, Plets M, *Morrison G, *Cunha A, *Xu T, et al. Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate sensitive prostate cancer (SWOG S1216). Clin Cancer Res, 2021. PMID: 33500355.
*Xu T, Li HT, *Wei J, Li M, Hsieh TC, *Lu YT, Lakshminarasimhan R, Xu R, *Hodara E, *Morrison G, Gujar H, Rhie, SK, Siegmund K, Liang G, Goldkorn A. Epigenetic Plasticity Potentiates a Rapid Cyclical Shift to and From an Aggressive Cancer Phenotype. Int J Cancer 146(11) 2020, PMID: 32017074.
*Morrison GJ, *Cunha A, *Jojo N, *Xu T, *Xu Y, Kwok E, Robinson P, Dorff T, Quinn D, Carpten J, Manojlovic Z, Goldkorn A. Cancer Transcriptomic Profiling From Rapidly Enriched Circulating Tumor Cells. Int J Cancer 146(10) 2020, PMID: 32037533.
*Hodara E, *Morrison G, *Cunha A, *Zainfeld D, * Xu T, *Xu Y, Dempsey PW, Pagano PC, Bischoff F, Khurana A, Koo S, Ting M, Cotter PD, Moore MW, Gunn S, Usher J, Rabizadeh S, Danenberg P, Danenberg K, Carpten J, Dorff T, Quinn D, Goldkorn A. Multi-parametric liquid biopsy analysis in metastatic prostate cancer. JCI Insight 4(5) 2019, PMID: 30702443.
*Hu BR, *Fairey AS, *Madhav A, Yang D, Li M, Groshen S, Stephens C, *Kim PH, *Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, *Xu T, *Xu Y, Gill IS, Quinn DI and Goldkorn A. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate, 76(6), 2016. PMID: 26771938.
Goldkorn A, Ely B, Tangen CM, Tai YC, *Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI: Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase 3 metastatic castration-resistant prostate cancer trial. Int J Cancer 136(8) 2015. PMID: 25219358.
Goldkorn A, Ely, B, Quinn, DI, Tangen, CM, Fink, LM, *Xu, T, Twardowski, P, Van Veldhuizen, PJ, Agarwal, N, Carducci, MA, Monk, JP, Datar, RH, Garzotto, M, Mack, PC, Lara, P, Higano, CS, Hussain, M, Thompson, IM, Cote, RJ, Vogelzang, NJ: Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32(11):1136-1142, 2014. PMID: 24616308
*He K, *Xu T, *Xu Y, Ring A, Kahn M, Goldkorn A: Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. Int J Cancer 134:43-54, 2014. PMID: 23784558.
Quinn DI, Tangen CM, Hussain M, Lara Jr PN, Goldkorn A, Garzotto MG, Mack PC, Carducci M, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr: Docetaxel and atrasentan compared to docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomized phase 3 trial. Lancet Oncol 14(9):893-900, 2013. PMID: 23871417.
*He K, *Xu T, Goldkorn A: Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther 10(6):938-948, 2011. PMID: 21518726.
*Xu T, Lu B, Tai YC, Goldkorn A: A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on microfilter. Cancer Res 70(16):6420-6426, 2010. PMID: 20663903.
Recent reviews:
*Lu Y-T and Goldkorn A. Current status of liquid biopsies for the detection and management of prostate cancer, invited review, Cancer Management and Research 2019, PMID: 31239778.
*Tulpule V, *Morrison GJ, et al and Goldkorn A. Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. In press. PMID: 35575959.
